Stop by our booth #906 to learn how our our cell-free HPV DNA assay and comprehensive liquid biopsy services can uncover insights complementing radiation oncology!
September 29 – October 1, 2024
Washington, DC
astro.org
Together for a better healthcare journey
We are committed to providing unwavering support to oncologists and clinical partners at every stage of the clinical drug development. Our aim is to deliver seamless end-to-end solutions without any compromises or unnecessary complexities. Our extensive portfolio includes a wide range of ultrasensitive NGS services in CLIA-validated lab with an exceptional project management team that sets us apart.
Our assays
Our vast portfolio of molecular assays yields informative data from cfDNA & cfRNA samples, aiding in therapeutic monitoring biomarker identification in nearly all cancer indications.
cfHPV DNA Assay:
HPV-SEQ
With the ability to reliably and consistently detect as low as 2 copies of cfHPV-DNA, HPV-SEQ makes a powerful tool for surveillance and monitoring during development of cancer therapies for HPV driven cancers.
Targeted Panel Assays:
Plasma-Safe-SeqS (PSS) Technology
Detecting low frequency somatic variants requires ultrasensitive liquid biopsy approaches. Our targeted approach balances the primary need for high sensitivity with the breadth of genomic coverage, providing confidence that somatic variants can be detected even at exceedingly low concentrations.
Broad Panel Assays:
Liquid Trace and Profile Plus Technology*
Our approach provides high sensitivity and specificity across a large set of genes. Our RNA capabilities go beyond fusion detection to include analyzing exon skipping, alternative splicing and gene expression.
Meet us at ASTRO
To meet with our team at ASTRO, please complete this form and a team member will reach out to schedule a live meet and greet.
Details about how we process your information are available in our Privacy Policy.